Sacituzumab govitecan: an antibody–drug conjugate

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–674.
   PubMed Web of Science ®Google Scholar
• Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. Annu Rev Med. 2012;63:185–198.
   PubMed Web of Science ®Google Scholar
• Faltas B, Goldenberg DM, Ocean AJ, et al. Sacituzumab govitecan, a novel antibody–drug conjugate, in patients with metastatic platinum-resistant urothelial carcinoma. Clin Genitourin Cancer. 2016;14:e75–e9.
   PubMed Web of Science ®Google Scholar
• Thomas A, Teicher BA, Hassan R. Antibody–drug conjugates for cancer therapy. Lancet Oncol. 2016;17:e254–e62.
   PubMed Web of Science ®Google Scholar
• Klute K, Nackos E, Tasaki S, et al. Microtubule inhibitor-based antibody–drug conjugates for cancer therapy. Onco Targets Ther. 2014;7:2227–2236.
   PubMed Web of Science ®Google Scholar
• Junutula JR, Flagella KM, Graham RA, et al. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer. Clin Cancer Res. 2010;16:4769–4778.
   PubMed Web of Science ®Google Scholar
• Garnock-Jones KP. Brentuximab vedotin: a review of its use in patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma following previous treatment failure. Drugs. 2013;73:371–381.
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Cardillo TM, Govindan SV, et al. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496–22512.
   PubMed Web of Science ®Google Scholar
• Starodub AN, Ocean AJ, Shah MA, et al. First-in-human trial of a novel anti-trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors. Clin Cancer Res. 2015;21:3870–3878.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Govindan SV, Sharkey RM, et al. Humanized anti-trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Am Assoc Cancer Res. 2011;17:3157–3169.
   Google Scholar
• Saber H, Leighton JK. An FDA oncology analysis of antibody-drug conjugates. Regul Toxicol Pharmacol. 2015;71:444–452.
   PubMed Web of Science ®Google Scholar
• Shvartsur A, Bonavida B. Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications. Genes Cancer. 2015;6:84–105.
   PubMedGoogle Scholar
• Cubas R, Zhang S, Li M, et al. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer. 2010;9:253.
   PubMed Web of Science ®Google Scholar
• Stepan LP, Trueblood ES, Hale K, et al. Expression of trop2 cell surface glycoprotein in normal and tumor tissues: potential implications as a cancer therapeutic target. J Histochem Cytochemistry. 2011;59:701–710.
   PubMed Web of Science ®Google Scholar
• Cardillo TM, Govindan SV, Sharkey RM, et al. Sacituzumab govitecan (IMMU-132), an anti-trop-2/SN-38 antibody-drug conjugate: characterization and efficacy in pancreatic, gastric, and other cancers. Bioconjug Chem. 2015;26:919–931.
   PubMed Web of Science ®Google Scholar
• Bignotti E, Todeschini P, Calza S, et al. Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. Eur J Cancer. 2010;46:944–953.
   PubMed Web of Science ®Google Scholar
• Fong D, Spizzo G, Gostner JM, et al. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol. 2008;21:186–191.
   PubMed Web of Science ®Google Scholar
• Trerotola M, Cantanelli P, Guerra E, et al. Upregulation of Trop-2 quantitatively stimulates human cancer growth. Oncogene. 2013;32:222–233.
   PubMed Web of Science ®Google Scholar
• Guerra E, Trerotola M, Aloisi AL, et al. The Trop-2 signalling network in cancer growth. Oncogene. 2013;32:1594–1600.
   PubMed Web of Science ®Google Scholar
• Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Am Assoc Cancer Res. 2002;8:641–661.
   Google Scholar
• Moon S-J, Govindan SV, Cardillo TM, et al. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem. 2008;51:6916–6926.
   PubMed Web of Science ®Google Scholar
• Umang S, Sanjay G, Sridhar M. Therapeutic targeting of CPT-11 induced diarrhea: a case for prophylaxis. Curr Drug Targets. 2013;14:777–797.
   PubMed Web of Science ®Google Scholar
• Lin H, Huang JF, Qiu JR, et al. Significantly upregulated TACSTD2 and cyclin D1 correlate with poor prognosis of invasive ductal breast cancer. Exp Mol Pathol. 2013;94:73–78.
   PubMed Web of Science ®Google Scholar
• Panowski S, Bhakta S, Raab H, et al. Site-specific antibody drug conjugates for cancer therapy. mAbs. 2014;6:34–45.
   PubMed Web of Science ®Google Scholar
• Elias DJ, Hirschowitz L, Kline LE, et al. Phase I clinical comparative study of monoclonal antibody KS1/4 and KS1/4-methotrexate immunconjugate in patients with non-small cell lung carcinoma. Cancer Res. 1990;50:4154–4159.
   PubMed Web of Science ®Google Scholar
• Ouyang J. Drug-to-antibody ratio (DAR) and drug load distribution by hydrophobic interaction chromatography and reversed phase high-performance liquid chromatography. In: Ducry L, editor. Antibody-drug conjugates. Totowa, NJ: Humana Press; 2013. p. 275–283.
   Google Scholar
• Goldenberg DM. Sacituzumab govitecan (IMMU-132), a next generation ADC in advanced clinical trials for solid cancer therapy. 2016. Available from: http://www.immunomedics.com/pdfs/PEGS%20Boston%202016.pdf
   Google Scholar
• Tagawa S, Faltas B, Lam E, et al. Treatment for metastatic platinum-resistant urothelial cancer (PRUC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience. New Orleans, LA: AACR; 2016.
   Google Scholar
• Bardia A, Diamond JR, Messersmith W, et al. Therapy of relapsed/refractory metastatic triple-negative breast cancer (mTNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase II results. New Orleans, LA: AACR; 2016.
   Google Scholar
• Bardia A, Vahdat LT, Diamond JR, et al. Therapy of refractory/relapsed metastatic triple-negative breast cancer (TNBC) with an anti-Trop-2-SN-38 antibody-drug conjugate (ADC), sacituzumab govitecan (IMMU-132): phase I/II clinical experience. J Clin Oncol. 2015;33 (suppl; abstr 1016).
   Google Scholar
• Breakthrough therapy designation for sacituzumab govitecan in triple-negative breastcancer. JoAD C. editor online: ADC Review; 2016. Available from: https://adcreview.com/news/breakthrough-therapy-designation-for-sacituzumab-govitecan-in-triple-negative-breast-cancer/
   Google Scholar
• FDA grants breakthrough therapy designation for sacituzumab govitecan for the treatment of TNBC. Eur Soc Med Oncol. 2016. Available from: http://www.esmo.org/Oncology-News/FDA-Grants-Breakthrough-Therapy-Designation-for-Sacituzumab-Govitecan-for-the-Treatment-of-TNBC
   Google Scholar
• Hamaguchi T, Doi T, Eguchi-Nakajima T, et al. Phase I study of NK012, a novel SN-38–incorporating micellar nanoparticle, in adult patients with solid tumors. Clin Cancer Res. 2010;16:5058–5066.
   PubMed Web of Science ®Google Scholar